Microbiome Therapeutics prepares to launch first microbiome modulator after completing Series B financing

261828b1-e8b6-4c71-a5dc-0270aa80590barticleimage.jpg

08 Nov 2017 --- MicroBiome Therapeutics, LLC (MBT), a company that applies the science of the gastrointestinal (GI) microbiome to promote health and wellness, has announced the completion of a Series B financing that raised approximately US$1 million. MBT intends to use the proceeds to launch its clinically-tested microbiome modulator product in 2018.

The dietary supplement is specifically designed to balance and optimize the GI tract and promote healthy metabolism by nourishing and nurturing the growth of healthful gut bacteria, MBT notes. New and existing investors include Lagniappe Angels, NO/LA Angel Network, Zehnder Communications and other private investors.

“We appreciate the support of our investors, which will enable the planned launch of our lead microbiome modulator next year,” says Dale Pfost, Acting CEO of MBT. “This product is a scientific formulation of natural ingredients designed to support a balanced GI microbiome and promote metabolic health in an easy-to-use, flavorful drink mix.”

“Our two clinical trials, conducted at the Pennington Biomedical Research Center and reported in peer-reviewed publications, demonstrated its benefits in helping to manage hunger, maintain healthy blood sugar levels and promote regularity,” Pfost adds.

The product is described as an all-natural blend of prebiotics, including fermentable fiber and polyphenol antioxidants in a patent-pending blend intended to help nurture and nourish beneficial microorganisms in the lower gut.

MBT reports that the launch of its microbiome modulator will be supported by a two-year e-commerce and social media campaign conducted in partnership with New Orleans-based advertising agency Zehnder Communications. MBT is also assembling a nationwide network of registered dietitians and certified diabetic educators to support the launch.

“With MicroBiome Therapeutics, we saw a unique opportunity to apply our product launch expertise in support of an exciting, first-in-class product from a leading science-based company,” says Jeremy Hunnewell, CFO and Business Strategist for Zehnder Communications. “We believe our expertise, along with our integrative and analytical approaches, will enable MBT to inform and educate consumers about this exciting new type of health-promoting dietary supplement.”

“Our investment reinforces our commitment to making a difference by playing a part in the microbiome revolution,” states Hunnewell, who will be joining the board of directors of MBT.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

Mushrooms hold potential for prebiotic diabetes treatment, study finds

17 Aug 2018 --- Eating white button mushrooms can create subtle shifts in the microbial community in the gut, which could improve the regulation of glucose in the liver, according to a team of Penn State College of Agricultural Sciences researchers. They also suggest that better understanding this connection between mushrooms and gut microbes in mice could one day pave the way for new diabetes treatments and prevention strategies for people.

Health & Nutrition News

Living by a forest diversifies kid’s micronutrient intake, study finds

17 Aug 2018 --- A global study has found that children who live near forests enjoy a better nutrition intake than those who live further away from them. The research, which was conducted across 27 developing countries, identified that children living by forests had at least 25 percent greater diversity in their diets compared to kids who did not. The study, published in Science Advances, notes particular nutrient increases with vitamin A and iron. The findings have the potential for actors attempting to lessen malnutrition through interventions such as fortification, by highlighting the benefit that could come from an integrated approach.

Health & Nutrition News

Low-carb diets could shorten life by four years, warns Lancet study

17 Aug 2018 --- Following a low-carb diet could shorten life expectancy by four years, suggests new research published in The Lancet Public Health. The high levels of animal fats and proteins that often replace carbohydrates in typical low-carb diets appear to be associated with the higher risk of mortality. Eating more plant-based proteins and fats in place of carbohydrates was linked to lower mortality and even reversed the greater mortality risk. 

Health & Nutrition News

Weekly Roundup: US consumers rank clean water as top health desire, high protein diet reduces risk of diabetes for those with fatty liver

17 Aug 2018 --- The weekly roundup is NutritionInsight's collection of global nutrition stories from the past week. A Nestlé Waters commissioned survey found that clean water is the most important health factor to US consumers and a study found that increasing the amount of protein in the diet may reduce the risk of diabetes in people with Non-Alcoholic Fatty Liver Disease (NAFLD). Australia based Freedom Foods acquired protein product brand Crankt to strengthen its position in the sports nutrition market. The European Commission (EC) approved an application from DSM Europe to rename the carotenoid zeaxanthin in the novel food register. CBI and Campden BRI are teaming up for a Colombian product development workshop and, lastly, the Council for Responsible Nutrition (CRN) announced eleven new additions to its membership ranks.

Health & Nutrition News

Molecular switch may serve as new target point for obesity and diabetes therapies, says study

16 Aug 2018 --- A mechanism of the PI3KC2A kinase enzyme may have significance for the future development of therapies against cancer, obesity and diabetes, research published in Molecular Cell has found. The study highlights how if specific signaling cascades are misregulated, diseases and metabolic disorders may occur. The identified mechanism may have a crucial influence on such signaling cascades.

More Articles
URL : http://www.nutritioninsight.com:80/news/microbiome-therapeutics-prepares-to-launch-first-microbiome-modulator-after-completing-series-b-financing.html